Anna Thor
Papers
3
Total Citations
29
H-Index
3
About
Anna Thor is a urological oncology researcher whose work centers on the surgical management of testicular cancer, particularly seminoma. She has established herself as a leading voice in evaluating retroperitoneal lymph node dissection (RPLND) as an alternative to chemotherapy and radiotherapy for patients with low-volume metastatic seminoma. Her research addresses a critical clinical challenge: while standard cytotoxic treatments achieve excellent survival rates, they carry significant long-term toxicities that diminish patients' quality of life. Through her prominent role in the Swedish Norwegian Testicular Cancer Group (SWENOTECA), Thor has contributed to landmark population-based and multi-institutional studies demonstrating the oncological efficacy and surgical safety of primary RPLND in stage IIA–IIC seminoma. Her most-cited work, published in 2024, has already garnered 19 citations within its first year, reflecting the immediate relevance of her findings to the field. Collaborating with international partners including the Cologne group, Thor's research is actively reshaping treatment paradigms and offering patients a viable path to cure while minimizing lasting treatment-related harm — a contribution with profound implications for survivorship in testicular cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3